Strides Pharma Science shares zoom 20% after company develops Favipiravir antiviral tablets
Shares of Strides Pharma Science Ltd on Wednesday zoomed 20 percent after the company said it has developed and commercialised Favipiravir antiviral tablets, and stressed that the drug has demonstrated positive outcomes in COVID-19 treatment globally
New Delhi: Shares of Strides Pharma Science Ltd on Wednesday zoomed 20 percent after the company said it has developed and commercialised Favipiravir antiviral tablets, and stressed that the drug has demonstrated positive outcomes in COVID-19 treatment globally.
The scrip advanced 20 percent to close at Rs 449.10, its upper circuit, on the BSE.
At the NSE, it climbed 20 percent to close at Rs 449.60.
"Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan. In February 2020, post the outbreak of Novel coronavirus (COVID-19), Favipiravir was studied in China and several other countries as an experimental treatment of COVID-19 ," the company said in a filing to the BSE.
"The drug has demonstrated positive outcomes, including a reduction in the duration of COVID-19 and improved lung conditions for the patients," it added.
It said Strides is the first Indian company to have commenced the export of Favipiravir tablets.
US lowers travel advisory for India: Why this change was made and travel situation with other countries
The United States' travel advisory comes as India recorded just 30,093 new coronavirus infections, its lowest in 125 days
COVID-19 vaccine production increasing, India may be first country to have DNA-based jab, Mansukh Mandaviya tells RS
Replying to a short discussion on COVID-19 management in Rajya Sabha, the minister said technology transfer to several companies has started and they will begin production in the coming days
Tracking the Indian women's hockey team's fortunes over the last two years heading into Tokyo 2020 Olympics